Rise in government focus on infection control programs, increase in the prevalence of hospital-acquired infections, and rise in adoption of technology advanced UV equipment fuel the growth of the global UV infection control market. On the other hand, high cost of UV infection control devices and stringent government regulation restrain the growth to some extent. However, high growth prospects in emerging markets is expected to create lucrative opportunities in the near future.
Global UV Infection Control Devices Industry garnered $317.42 million in 2018, and is expected to reach $524.84 million by 2026, growing at a CAGR of 6.5% from 2019 to 2026.
Frontrunners in the industry-
- CVS Health Corporation
- DocMorris
- Express Scripts Holding Company
- Giant Eagle Inc.
- Optum Rx Inc.
- Rowlands Pharmacy
- The Kroger Co.
- Walgreen Co.
- Walmart Stores Inc.
- Apollo Pharmacy.
North America to retain its dominance in terms of revenue-
Based on geography, North America accounted for more than two-fifths of the global UV infection control market revenue in 2026, and is projected to maintain the lion’s share from 2019 to 2026. The region is anticipated to maintain its dominance throughout the forecast period. This is attributed to the rise in the number of cases of HAIs and presence of key players lead to easy availability of these devices in this region. On the other hand, the region across Asia-Pacific is expected to manifest the fastest CAGR of 8.1% from 2020 to 2027. This is due to the improvements in health standards, surge in disposable incomes, and advancements in technology for the development of new UV infection control devices in this region.
SOURCE: Allied Market Research
0 Comments